Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mass balance and metabolite profiling of <sup>14</sup>C-Zalunfiban in humans following single-dose subcutaneous administration.

Xenobiotica; the fate of foreign compounds in biological systems·2025

Same author

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.

NEJM evidence·2025

Same author

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014-2019).

Frontiers in cardiovascular medicine·2023

Same author

[Aortic stenosis: An update].

La Revue de medecine interne·2022

Same author

[stent thrombosis : A won battle ? (data from the France PCI registry)].

Annales de cardiologie et d'angeiologie·2021

Same author

Prognostic value of longitudinal strain and ejection fraction in Friedreich's ataxia.

International journal of cardiology·2021

Search research articles

Related Experiment Video

Updated: May 22, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Current antiplatelet options for NSTE-ACS patients.

G Cayla¹, J Silvain, S A O'Connor

¹Institut de Cardiologie, Bureau 236, Pitié-Salpêtrière University Hospital, 47-83, Bld de l'Hôpital, 75013 Paris, France.

QJM : Monthly Journal of the Association of Physicians

|May 1, 2012

Summary

Newer antiplatelet drugs, ticagrelor and prasugrel, show greater effectiveness than clopidogrel for non-ST-elevation acute coronary syndrome (NSTE-ACS). These agents offer improved patient outcomes with manageable bleeding risks, aiding personalized treatment strategies.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 22, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

Cardiology
Pharmacology

Background:

Non-ST-elevation acute coronary syndrome (NSTE-ACS) is a common cardiovascular condition.
Platelet activation is a key factor in NSTE-ACS pathogenesis.
Dual antiplatelet therapy (DAPT) with aspirin is a standard treatment.

Purpose of the Study:

To review drugs used with aspirin for DAPT in NSTE-ACS.
To compare the efficacy and safety of clopidogrel, ticagrelor, and prasugrel.
To guide individualized treatment selection for NSTE-ACS patients.

Main Methods:

Literature review of clinical studies on antiplatelet therapies in NSTE-ACS.
Analysis of comparative effectiveness and safety data for clopidogrel, ticagrelor, and prasugrel.
Evaluation of factors influencing treatment outcomes, including patient comorbidities.

Main Results:

Ticagrelor and prasugrel are more effective than clopidogrel in NSTE-ACS patients.
These newer agents demonstrate acceptable tolerability and manageable bleeding risks.
Differences between ticagrelor and prasugrel suggest potential for tailored therapy.

Conclusions:

Ticagrelor and prasugrel represent advances over clopidogrel for NSTE-ACS.
Further head-to-head trials are needed to directly compare ticagrelor and prasugrel.
Individualizing NSTE-ACS treatment based on drug profiles can reduce morbidity and mortality.